Branded Generics
Meeting Medical Needs in Emerging Markets
Branded generics account for more than 80% of the market in India and almost 50% in China vs. just over 10% in the United States.
Branded generic pharmaceuticals, often original medicines no longer on patent, offer treatment at a lower cost but are equal in terms of quality, efficacy and safety – with a reliable supply.
By 2020, Brazil’s and India’s middle classes, largely consumers of branded generics, are expected to increase to 9.4 million and 200 million, respectively.
In emerging markets – where incomes are rising, middle classes are growing and many pay out of pocket for healthcare – there is a preference for branded generics.
Emerging markets currently account for more than 50% of global sales by volume and will reach 55% by 2020 as market access grows.
Generic
Undifferentiated commodity products
Branded Generic
Trusted quality and efficacy
Differentiated products
Innovative packaging and formulations, with more than 400 products in development
Region-specific portfolios
Focus on high-growth markets
Proprietary
Pharma
Higher-cost, higher-risk development
Finite periods of economic return
High costs that can limit patient access
Abbott’s pharmaceuticals business provides patients in emerging markets access to high-quality, affordable medicines. We have an endless drive to improve medicines and bring meaningful solutions to help people live healthier, fuller lives. We have distinguished ourselves by investing in emerging markets, which have rapidly growing middle classes, fast-growing and aging populations, rising chronic disease and a strong demand for recognized, quality medicines.
— Andrew Lane, Executive Vice President, Established Pharmaceuticals, Abbott
What's On Abbott's Branded Generics Shelf?
Core Therapeutic Areas5
Click the items on the shelves to learn more.*
*Indications and product availability vary by country. Products are not available in the United States. Brand rankings are based on ex-U.S. sales, per IMS.
**By volume
Gastroenterology
A wide range of treatments covering the gastroenterological tract, from the stomach to the intestines and their associated organs
Creon
No. 1 pancreatic enzyme replacement therapy
WomEn’s Health
Trusted brands for the treatment of many different gynecological disorders
Duphaston
No. 1 brand for progesterone deficiency
Cardiometabolic
Brand generics for the treatment of dyslipidemia and hypertension
Lipanthyl / Triocor / Lipidil
No. 1 fibrate
CNS/Pain
High-quality medicines for the treatment of Ménière’s disease, vestibular vertigo, pain, fever and inflammation
Brufen
No. 1 ibuprofen brand**
Respiratory
Treatments for mild to moderately severe infections caused by pathogens, such as respiratory tract infections
Klacid
No. 1 macrolide antibiotic
Influenza Vaccine
Influenza vaccine with more than 25 years’ proven results for children, adults, the elderly and high-risk patient groups
First Halal
Certified flu vaccine
10.5%
EPD sales growth in 2016 (double-digit growth in key emerging markets)
125+
year reputation for quality, reliability, and world-class scientific culture and expertise
$3.9
billion
in sales (2016)
31
manufacturing sites
12
development centers
Diverse Portfolio
Abbott’s established pharmaceuticals business brings value to patients and customers globally through a growing portfolio of high-quality medicines, by building country-specific portfolios of trusted products to suit local patient needs.
Click on the green circles for more information.
LATIN AMERICA
Abbott is a top-10 pharmaceutical company in Latin America and holds No. 1 positions in Chile, Colombia and Peru. Abbott’s strong footprint in the region includes manufacturing and R&D facilities in Argentina, Brazil, Chile, Colombia, Mexico and Peru, enabling us to bring trusted high-quality medicines, tailored to the people who rely on them.
RUSSIA
Abbott continues to deepen its footprint in Russia and is among the top-5 branded generics companies in Russia, following the strategic acquisition of Veropharm in 2014.
INDIA
India comprises more than 20% of Abbott’s branded generic pharmaceutical sales, driven by locally relevant portfolio expansion. About 80% of India’s population lacks health insurance, meaning they rely on doctors to help them choose medicines that are affordable but also high quality.
CHINA
By 2020, three out of four urban households in China will be classified as middle class. Abbott has been part of this fast-changing and growing healthcare market for two decades and continues to meet the evolving needs of the country with localized branded generic solutions.
Localized Strategy
A global presence with localized distribution channels ensures reliable supply and distribution of high-quality products. Co-located manufacturing and development centers increase the speed at which Abbott products reach markets, and they are globally powered to quickly share and leverage innovation across multiple geographies.
Abbott has been delivering high-quality medicine for nearly 130 years. This has built up a great deal of trust, and consumers in emerging markets know they can depend on our quality.
Abbott’s global scale and local presence position the company for long-term success in emerging markets. Global scale provides a solid base to remain competitive, particularly when it comes to manufacturing and innovation efficiencies. Local decision-making makes Abbott nimble and flexible to adapt to fast-changing, complex markets.
As doctors and pharmacies continue to recommend Abbott branded generics to address local healthcare needs, consumers continue to build trust and affinity with Abbott’s products.
We have an endless drive to bring meaningful innovation to our markets – in both medicines and the services that go along with them – to help people live healthier, fuller lives.
Value is created by meaningful innovation and improvement, driven by patient needs and patient use.
- New forms
- New indications
- Differentiated packaging
- Consumer choice/preference
- Services
Sources:
© 2017 Abbott. All Rights Reserved. Please read the Legal Notice for further details. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.